MX2020013924A - Composicion inmunogena para paratuberculosis. - Google Patents
Composicion inmunogena para paratuberculosis.Info
- Publication number
- MX2020013924A MX2020013924A MX2020013924A MX2020013924A MX2020013924A MX 2020013924 A MX2020013924 A MX 2020013924A MX 2020013924 A MX2020013924 A MX 2020013924A MX 2020013924 A MX2020013924 A MX 2020013924A MX 2020013924 A MX2020013924 A MX 2020013924A
- Authority
- MX
- Mexico
- Prior art keywords
- paratuberculosis
- immunogenic composition
- map
- polypeptide
- infection
- Prior art date
Links
- 208000026681 Paratuberculosis Diseases 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004897 n-terminal region Anatomy 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811382.9A GB201811382D0 (en) | 2018-07-11 | 2018-07-11 | Vaccine |
| PCT/GB2019/051933 WO2020012177A1 (en) | 2018-07-11 | 2019-07-10 | Immunogenic composition for paratuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013924A true MX2020013924A (es) | 2021-03-02 |
Family
ID=63273113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013924A MX2020013924A (es) | 2018-07-11 | 2019-07-10 | Composicion inmunogena para paratuberculosis. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12186382B2 (enExample) |
| EP (1) | EP3820507A1 (enExample) |
| JP (2) | JP2021524485A (enExample) |
| KR (1) | KR20210033490A (enExample) |
| CN (1) | CN113329765A (enExample) |
| AU (1) | AU2019301899A1 (enExample) |
| BR (1) | BR112021000312A2 (enExample) |
| CA (1) | CA3105763A1 (enExample) |
| GB (1) | GB201811382D0 (enExample) |
| IL (1) | IL280070B2 (enExample) |
| MA (1) | MA53131A (enExample) |
| MX (1) | MX2020013924A (enExample) |
| SG (1) | SG11202100120TA (enExample) |
| WO (1) | WO2020012177A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700487D0 (en) * | 2017-01-11 | 2017-02-22 | Hermon-Taylor John | Diagnostic |
| WO2026041756A1 (en) | 2024-08-21 | 2026-02-26 | Hav Vaccines Limited | Treatment of crohn's disease by mycobacterium avium subsp. paratuberculosis agent |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5225324A (en) | 1987-04-24 | 1993-07-06 | Bioscience International, Inc. | Diagnostics for mycobacteria in public health, medical, and veterinary practice |
| GB8709803D0 (en) | 1987-04-24 | 1987-05-28 | Mcfadden J J | Treatment of crohn's disease &c |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| JPH07505283A (ja) | 1992-03-20 | 1995-06-15 | ベイラー・カレッジ・オブ・メディシン | Ｄｎａトランスポーター系および使用方法 |
| AU682308C (en) | 1992-04-03 | 2006-08-17 | Regents Of The University Of California, The | Self-assembling polynucleotide delivery system |
| US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
| GB9526178D0 (en) | 1995-12-21 | 1996-02-21 | Taylor John Hermon | Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy |
| GB9806093D0 (en) | 1998-03-20 | 1998-05-20 | Taylor John Hermon | Diagnostics and vaccines for mycobacterial infections of animals and humans |
| US7074559B2 (en) * | 2002-03-06 | 2006-07-11 | Refents of the University of Minnesota | Mycobacterial diagnostics |
| ATE466876T1 (de) | 2005-08-09 | 2010-05-15 | Hav Vaccines Ltd | Immunogene konstrukte |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CN102596236B (zh) | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
| EP2710151A4 (en) | 2011-05-19 | 2014-12-10 | Univ Central Florida Res Found | MICROBEND DETECTION BY HYBRIDIZATION OF MAGNETIC RELAXATION NANOSENSORS |
| WO2014016737A1 (en) | 2012-07-24 | 2014-01-30 | Pfizer Inc. | Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof |
| JP2016513078A (ja) * | 2013-01-28 | 2016-05-12 | ダンマルクス テクニスケ ウニベルシテット | 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン |
| GB201700487D0 (en) * | 2017-01-11 | 2017-02-22 | Hermon-Taylor John | Diagnostic |
-
2018
- 2018-07-11 GB GBGB1811382.9A patent/GB201811382D0/en not_active Ceased
-
2019
- 2019-07-10 KR KR1020217004231A patent/KR20210033490A/ko not_active Ceased
- 2019-07-10 CA CA3105763A patent/CA3105763A1/en active Pending
- 2019-07-10 JP JP2021500530A patent/JP2021524485A/ja active Pending
- 2019-07-10 MA MA053131A patent/MA53131A/fr unknown
- 2019-07-10 IL IL280070A patent/IL280070B2/en unknown
- 2019-07-10 WO PCT/GB2019/051933 patent/WO2020012177A1/en not_active Ceased
- 2019-07-10 BR BR112021000312-6A patent/BR112021000312A2/pt unknown
- 2019-07-10 MX MX2020013924A patent/MX2020013924A/es unknown
- 2019-07-10 AU AU2019301899A patent/AU2019301899A1/en not_active Abandoned
- 2019-07-10 SG SG11202100120TA patent/SG11202100120TA/en unknown
- 2019-07-10 US US17/259,075 patent/US12186382B2/en active Active
- 2019-07-10 CN CN201980059761.5A patent/CN113329765A/zh active Pending
- 2019-07-10 EP EP19752222.0A patent/EP3820507A1/en active Pending
-
2024
- 2024-07-05 JP JP2024109065A patent/JP2024153666A/ja active Pending
- 2024-11-20 US US18/954,032 patent/US20250152691A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210338791A1 (en) | 2021-11-04 |
| IL280070A (en) | 2021-03-01 |
| JP2021524485A (ja) | 2021-09-13 |
| IL280070B1 (en) | 2023-12-01 |
| US20250152691A1 (en) | 2025-05-15 |
| IL280070B2 (en) | 2024-04-01 |
| CN113329765A (zh) | 2021-08-31 |
| CA3105763A1 (en) | 2020-01-16 |
| KR20210033490A (ko) | 2021-03-26 |
| MA53131A (fr) | 2021-05-19 |
| SG11202100120TA (en) | 2021-02-25 |
| JP2024153666A (ja) | 2024-10-29 |
| GB201811382D0 (en) | 2018-08-29 |
| EP3820507A1 (en) | 2021-05-19 |
| WO2020012177A1 (en) | 2020-01-16 |
| AU2019301899A1 (en) | 2021-01-14 |
| BR112021000312A2 (pt) | 2021-04-13 |
| US12186382B2 (en) | 2025-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501520A1 (en) | Fusarium toxin-cleaving polypeptide variants, additives containing same, use of same, and method for splitting fusarium toxins | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| JP2015214545A5 (enExample) | ||
| JP2014000092A5 (enExample) | ||
| BR112017020308A2 (pt) | udp-glicosiltransferases | |
| EA202190240A1 (ru) | Варианты рекомбинантного белка | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| AR100942A1 (es) | Composiciones y método para el control glucémico que comprenden albiglutida | |
| MX2019009551A (es) | Enzima lipolitica para usarse en horneado. | |
| AU2018280528A8 (en) | Method for improving transformation efficiency of plant and method for transforming plant | |
| MX2021001507A (es) | Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer. | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| EP3103471A3 (en) | Acinetobacter baumanii antigens and the uses thereof | |
| MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
| PH12018500468A1 (en) | Fusion protein | |
| NZ729514A (en) | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis | |
| AR101146A1 (es) | Proteína con actividad xilanasa | |
| PH12017502323A1 (en) | Novel xylanase | |
| WO2015108856A3 (en) | Methods for enhancing the delivery of active agents | |
| MX2018012716A (es) | Peptidos bioactivos pegilados y usos de los mismos. | |
| MX2017016438A (es) | Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit. | |
| MX2020007336A (es) | Metodos y composiciones para modular la disfuncion de celulas endoteliales. | |
| BR112013002702A2 (pt) | vacina | |
| PH12020551339A1 (en) | MUTANTá-GLUCOSIDASE | |
| MX2018006823A (es) | Una composicion para mejorar la memoria, capacidad de aprendizaje y capacidad cognitiva. |